Agape ATP Corporation (ATPC) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Agape ATP Corp (ATPC) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, Agape ATP is a very small health care company whose balance sheet looks unusually clean, but the core business is still tiny, shrinking, and losing money. > **📍 Basic Profile** > > Market Cap **$3.59 million** · Health Care · NASDAQ NMS - GLOBAL MARKET · Price **$3.59** > **⚡ 3 Things You Should Know** > > 1. 💰 Gross margin looks decent at 55%, but that does **not** mean the business is healthy—operating margin is **-213.65%** and net margin is **-149.57%**, which basically means overhead is overwhelming a very small revenue base. > > 2. ⚠️ The balance sheet is surprisingly light on debt, with debt-to-equity of just **0.0057** and a current ratio above **11x**; in other words, insolvency risk looks low for now, but that safety cushion hasn’t translated into a workable profit model yet. > > 3. 📉 This is more of a speculative trading name than a proven operating story right now—the stock jumped **71.8%** in a day, yet it still sits massively below its **$119** 52-week high, which tells you sentiment and volatility are driving the stock more than fundamentals. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin -149.57%, deeply loss-making | > | Growth Rate | Slow🐢 | 3-year revenue growth -6.42% | > | Financial Health | Healthy💚 | Debt ratio ~0.57%, current ratio 11.82 | > | Valuation | [Data unavailable] | PE unavailable; P/S 2.36x, P/B 0.24x | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Health care-related products/services sold to consumers or distributors, making money through product sales—but the current revenue base is very small. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Core health care products/services | [Data unavailable] | ↓ | Revenue appears to be contracting over multi-year periods | | Other segments | [Data unavailable] | [Data unavailable] | No segment split provided | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 55% | Average to Good | Product-level margin is not the issue; the problem is cost structure beyond gross profit | | Net Margin | -149.57% | Below Average | The company is losing far more than it earns in sales, which is a major red flag | | ROE | -9.83% | Average to Below Average | Shareholder capital is not generating positive returns | --- #### 📈 How's the Growth? **Growth Assessment:** Slowing / Stagnant | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | Q1 sales down to $273.7K from $289.0K | Slowing | | Profit Growth | [Data unavailable] | EPS loss improved to $(0.33) from $(3.63) | Improving from a weak base | **Growth Quality:** > What's interesting is that reported EPS losses have improved a lot year over year, but revenue is still tiny and down slightly. Basically, that suggests the improvement may be coming more from cost adjustments or easier comparisons than from real business momentum. --- #### 💰 Financial Health Check **One Sentence:** This looks like someone with almost no debt and plenty of near-term liquidity, but not much income coming in. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 0.57% | <60% safe | ✅Safe | | Current Ratio | 11.82 | >1.5 healthy | ✅Safe | | Cash Flow | -$0.02365/share | >0 | 🚨Negative | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $1.721 - 52-Week High: $119 - Current: $3.59, Near the low | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(1.6% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | [Data unavailable] | 5-year avg [Data unavailable] | [Data unavailable] | | vs Peers | P/S 2.36x | Industry avg [Data unavailable] | [Data unavailable] | **What the Current Valuation is Betting On:** > At this price, the market is not valuing ATPC like a high-confidence growth story. The very low P/B of 0.24x suggests investors are skeptical about asset quality, future profitability, or both. In other words, the stock looks "cheap" only if the company can prove the business can stabilize and scale. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-05-21 | Stock surged in pre-market/intraday mover lists | Neutral | More about trading momentum than business fundamentals | | 2026-05-14 | Q1 EPS $(0.33) vs $(3.63) YoY; sales $273.7K vs $289.0K YoY | Mixed | Losses improved sharply, but revenue still declined | | 2026-04-12 | Q4 EPS $(0.35); sales $399.1K | Neutral | Still loss-making, though comparisons suggest less severe losses than before | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 55% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -149.57% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -9.83% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | ↓ | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2024-12-31 | [Data unavailable] | $(0.20) | [Data unavailable] | | 2023-09-30 | [Data unavailable] | $0.00 | [Data unavailable] | | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Earnings Trend Interpretation:** The main thing here is not analyst beats or misses—because that data is missing—but that the company remains inconsistently profitable and still posts losses. So the better question is whether losses are narrowing for durable reasons, not whether it "beat" a low bar. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 0 firms | 0% | | Hold | 0 firms | 0% | | Sell | 0 firms | 0% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net [Data unavailable] in past 3 months > No analyst coverage and no insider transaction data usually means this is flying under the radar. For a micro-cap like this, that can mean opportunity—but more often it means less external scrutiny and higher risk. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Business Model Risk:** Revenue is extremely small and has been shrinking over longer periods → If this continues, the company may struggle to build operating leverage or justify being public. 2. **Profitability Risk:** Net and operating margins are deeply negative despite decent gross margin → If overhead stays too high, cash burn could continue even without debt pressure. 3. **Trading/Volatility Risk:** The stock can move violently on low-float momentum rather than fundamentals → If sentiment reverses, the share price could swing sharply in either direction. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Agape ATP is a tiny NASDAQ-listed health care company with a very small revenue base and a highly speculative stock profile. > > **Key strength:** Its balance sheet looks unusually clean, with almost no leverage and very strong short-term liquidity. > > **Key risk:** The core issue is simple: sales are tiny, growth is weak, and losses are still far too large relative to revenue. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis